Rebate Game Played By PBMs And Drug Makers Limits Biosimilar Competition
The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
pharmaphorum5h
Aignostics leads latest crop of digital health financings
Recent funding rounds in the digital health arena feature digital pathology startup Aignostics, remote care specialists TCC, ...
German pharmaceutical company sees great benefits from CIIE's spillover effect
STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...
‘Sick day’ on the clock: CT Biopharma firm expands patient simulations to spark creativity, empathy
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
FierceBiotech10d
Boehringer Ingelheim drops obesity drug from Gubra partnership
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
The Pharma Letter7d
Boehringer mental health tie-up worth up to $126.5 million to Broad Institute
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...
dvm36011d
Boehringer Ingelheim announces research and development facility expansion
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...